Webwww.slidescarnival.com WebMar 24, 2024 · CAMBRIDGE, Mass., March 24, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that it has filed a revised definitive proxy statement with the Securities and Exchange Commission (SEC) in connection with a …
Home - Akebia Therapeutics
WebMar 9, 2024 · CAMBRIDGE, Mass., March 9, 2024 /PRNewswire/ — Akebia Therapeutics ®, Inc. ( Nasdaq: AKBA ), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full-year ended December 31, 2024 and provided business highlights. WebMar 13, 2024 · Akebia Therapeutics, Inc. (NASDAQ: AKBA) Q4 2024 Earnings Call Transcript March 9, 2024 Operator: Good day ladies and gentlemen. Thank you for … body dysphoria vs gender dysphoria
www.slidescarnival.com
WebApr 7, 2024 · CAMBRIDGE, Mass., April 7, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present posters at the National Kidney Foundation (NKF) Spring Clinical Meetings 2024 (SCM23), which will … WebApr 10, 2024 · CAMBRIDGE - Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present posters at the National Kidney Foundation (NKF) Spring Clinical Meetings 2024 (SCM23), which will take place on … WebNov 3, 2024 · Akebia Therapeutics, Inc. (NASDAQ:NASDAQ:AKBA) Q3 2024 Results Conference Call November 3, 2024 4:30 PM ETCompany ParticipantsMercedes Carrasco - Senior Director of Corporate... body dysmorphic symptoms scale bdss